Wegovy pill is the once-daily oral semaglutide presentation FDA-approved in December 2025 for long-term weight reduction in qualifying adults and reduction of major cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity. It is a prescription medicine, not an OTC weight-loss supplement and not the same product as Ozempic tablets.
The oral Wegovy family includes FDA-approved 1.5 mg, 4 mg, 9 mg and 25 mg tablets, with product-specific instructions that affect absorption. The existence of oral and injectable Wegovy does not mean they have identical eligible patient groups, schedules or approved uses. Wegovy injection also has pediatric weight-management labeling and a certain MASH indication that should not be casually generalized to tablets.
This page identifies the oral product, its approved adult use, packaging and how its tablet requirements affect shopping decisions. For the pharmacy transaction use the Wegovy pill purchase guide. Compare daily tablets to injections at Wegovy pill versus pen, or return to the Wegovy brand-family overview.
Novo Nordisk announced FDA approval for Wegovy tablets on December 22, 2025 following the OASIS clinical development program. The oral product is a branded semaglutide tablet for eligible adults with obesity or overweight with a qualifying related condition, used with a reduced-calorie diet and increased physical activity. It also has labeled major cardiovascular event risk-reduction use in adults with established cardiovascular disease and obesity or overweight.
One should not infer identical eligibility with the standard injection: pediatric obesity labeling and the accelerated-approval noncirrhotic MASH indication belong to the appropriate injection product label. The clinician must consider the precise presentation and its individual labeling before prescribing.
FDA-approved Wegovy oral strengths are 1.5 mg, 4 mg, 9 mg and 25 mg. These numbers identify specific tablet presentations and label frameworks, not a menu for independent strength selection. The prescribing professional follows product-specific labeling and clinical monitoring; the patient should confirm the actual strength listed on the prescription and dispensed bottle.
A pharmacy listing for an oral semaglutide tablet with the same number of milligrams does not establish that it is the Wegovy brand or is authorized for the same indication. The matrix below separates commonly confused semaglutide oral and injection offerings.
| Product family | Dosage form and U.S. strengths | Main distinction | Focused page |
|---|---|---|---|
| Wegovy tablets | Daily tablet: 1.5, 4, 9, 25 mg | Adult weight reduction and specific CV risk reduction | Tablet access |
| Wegovy standard pen | Once-weekly injection with pen-specific strengths | Different administration; some adolescent and MASH label contexts | Wegovy overview |
| Wegovy HD | 7.2 mg once-weekly injection | Higher-dose adult weight reduction product | HD profile |
| Ozempic tablets | Daily oral tablet: 1.5, 4, 9 mg | Different brand and adult type 2 diabetes indications | Ozempic pill |
Wegovy tablets rely on a formulation that permits gastrointestinal absorption of semaglutide. Official instructions describe taking the tablet on an empty stomach with a limited amount of plain water and waiting before other food, drink or oral medicines. A consistent routine is therefore a meaningful consideration when a prescriber discusses the pill rather than a weekly injection.
Patients should follow the exact Medication Guide and individualized clinician or pharmacist advice, not mix instructions from Ozempic pens, older Rybelsus products or another GLP-1 tablet. Avoid splitting, chewing or improvising tablet use. A provider can help assess whether the labeled routine is workable for a given person.
Wegovy pills are supplied as tablets in product-specific packaging rather than weekly injection pens. The manufacturer directs patients to keep them in their original closed bottle and protect against moisture, with tablet-specific room-temperature storage conditions. This is different from the refrigerated handling that may apply to particular injection presentations.
When receiving a shipment, verify product name, strength, container integrity and expiration information, and contact a licensed pharmacist if the bottle appears damaged or the label does not match your prescription. Do not assume that a website advertising “Wegovy in stock” means the tablet presentation is available.
Wegovy oral approval was supported by clinical research in defined populations, including the OASIS program. Published manufacturer summaries discuss body-weight changes with oral semaglutide when combined with lifestyle intervention, but clinical results depend on the trial population, adherence, endpoint definition and follow-up duration. A single headline percentage is not a personalized prognosis.
For a direct comparison of oral versus injectable forms, see the formulation comparison. That page can clarify study design and practical tradeoffs without implying that outcomes from different trials are directly interchangeable.
An adult seeking help with weight management may qualify for clinical assessment based on obesity or overweight with a weight-related condition, but the clinician must evaluate the complete labeling and medical history. The cardiovascular indication refers to adults with established cardiovascular disease and either obesity or overweight; it is not a blanket statement that all adults taking a Wegovy tablet receive a specific benefit.
A person researching semaglutide for type 2 diabetes instead should review Ozempic labeled uses rather than mistake the branded Wegovy pill for a generic oral diabetes prescription. FDA indications and payer decisions must be kept separate.
Confirm the exact oral Wegovy strength, quantity, prescription directions and any insurer or self-pay terms. The pharmacy should be authorized to dispense in the relevant state and able to identify the real product. Prescription-only medicine sold with no clinician review, a fake FDA seal or a foreign-language label is a red flag.
The oral Wegovy buying guide handles tablet-specific checkout and fulfillment. The licensed pharmacy checklist covers verification rather than implying a named seller has current stock.
An advertised pen price may cover a different supply unit, route, insurance benefit or promotion from a 30-tablet bottle. Similarly, a manufacturer self-pay program may limit eligibility by product strength, date, patient coverage or pharmacy channel. Compare the exact oral product and supply duration before drawing a financial conclusion.
Use Wegovy cost methodology for brand-specific costs and Wegovy insurance for plan terms. No current price or inventory is guaranteed by this page.
Wegovy tablets carry important warnings and contraindications. FDA labeling includes a boxed warning about thyroid C-cell tumors observed in rodents, and restrictions involving personal or family history of medullary thyroid carcinoma or MEN 2. Clinicians must also consider gallbladder disease, pancreatitis, severe gastrointestinal adverse reactions, kidney problems associated with fluid depletion, certain interactions and other presentation-specific precautions.
Weight-loss treatment choices are individualized, and use with other GLP-1 receptor agonists or semaglutide products is not routinely recommended by labeling. A doctor or pharmacist should address pregnancy planning, other medications and any concerning symptoms; a shopping guide cannot clear a patient for treatment.
All three names have been associated with oral semaglutide, but the U.S. Wegovy tablets have weight-management/CV indications and a 25 mg strength, while current Ozempic tablets have type 2 diabetes-oriented indications and the older Rybelsus line was phased out domestically. Equal numeric strength does not mean equal authorized use.
If a pharmacy attempts to substitute a different brand or oral product, request a clinician and pharmacist review. The Rybelsus transition guide addresses historical brand changes, not a license to exchange products yourself.
Wegovy pill is an option for adults who want an oral formulation, but swallowing a tablet daily requires attention to the label’s empty-stomach conditions. A weekly pen avoids daily tablet timing but introduces device handling and storage. Consider both practical routines with a clinician while keeping evidence and the product-specific FDA indication central to the decision.
An online store cannot determine which routine is medically appropriate. Even if two regimens share semaglutide as an active ingredient, the dose strengths and instructions cannot be assumed equivalent. The distinction is especially important when other morning oral medicines are used.
Ask whether the U.S.-licensed pharmacy can identify the exact Wegovy tablet strength and bottle, whether it has a valid prescription, and how it handles payer adjudication or self-pay eligibility. Request the pharmacist’s labeled storage and administration counseling. A general Wegovy listing may refer only to injection and therefore should not be treated as confirmation of the oral product.
If a service offers to replace the tablet with a compounded liquid, non-U.S. semaglutide or a different brand, request a clinician review before proceeding. Do not infer FDA equivalence from an identical ingredient name or a matching numeric strength.
The oral Wegovy approval, strengths and product requirements summarized here reflect current U.S. labeling and official manufacturer information reviewed October 18, 2026. This page does not offer a clinical dose-escalation schedule, attest live stock or substitute for the full product labeling.
Some outbound commercial links may be affiliate or sponsored referrals, meaning this independent information site may receive compensation if readers use them. Commercial relationships do not establish product suitability, pharmacy licensing or prescription eligibility; any compensation is identified alongside the relevant outbound link.
Yes. FDA approved oral Wegovy tablets in December 2025 for labeled adult long-term weight reduction and specified cardiovascular risk reduction.
The U.S. oral presentations include 1.5 mg, 4 mg, 9 mg and 25 mg tablets. Strength selection and changes belong to the prescriber.
The oral product is labeled for adults. The standard Wegovy injection has separate weight-management labeling for certain adolescents aged 12 and older.
No. They contain semaglutide but are different branded products with distinct FDA-labeled uses and product instructions.
The tablet has specific administration rules involving an empty stomach, plain water and a waiting interval. Follow the official medication instructions provided with your prescription.
Wegovy tablets have product-specific room-temperature storage instructions and should remain in the original closed container; do not apply pen refrigeration rules to tablets.
No. Wegovy tablets are prescription-only in the United States.
No. Do not transfer the injection-specific noncirrhotic MASH indication to the oral tablet product.
Costs depend on product, strength, supply duration, insurance and savings eligibility. An injection pack quote is not a reliable tablet bottle price.